CaMKK2 Identifies Biologically Aggressive Chronic Lymphocytic Leukemia and Regulates Leukemic Survival and Nurse-Like Cell Support
This study identifies elevated CaMKK2 expression as a prognostic biomarker for biologically aggressive chronic lymphocytic leukemia (CLL) and demonstrates that inhibiting CaMKK2 reduces leukemic cell survival and disrupts supportive nurse-like cell interactions, highlighting its potential as a therapeutic target for high-risk patients.